contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


virogates-announces-financial-guidance-for-2026

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Virogates is active in medical technology. The company is active in research and development of biomarkers and diagnostic instruments for the healthcare industry. The products are sold under various brands and are used in the identification, analysis and further treatment of diseases, primarily cardiovascular diseases, cancer and neurological diseases. The company was established in 2001 and is headquartered in Birkerød.

Virogates

Company Announcement no. 22/2025 (December 12, 2025)BIRKERØD, DENMARK—ViroGates A/S (“ViroGates” or the “Company”), a medical technology company developing blood tests for measuring chronic ...

<div class="mfn-header mfn-header-denmark">Company Announcement no. 22/2025 (December 12, 2025)</div><div class="mfn-body">BIRKERØD, DENMARK—ViroGates A/S (“ViroGates” or the “Company”), a medical technology company developing blood tests for measuring chronic inflammation at health clinics and hospitals, announces its financial guidance for 2026.ViroGates expects full-year revenue between DKK 6 and 7 million and an EBIT of DKK -10 to -12 million in 2026. ViroGates continues to pause its guidance to the market regarding achieving positive cash flow.Entering 2026, ViroGates expects to have completed most of the funded analytical work related to the collaboration with Sobi aimed at obtaining U.S. marketing clearance for suPARnostic® TurbiLatex. The collaboration will, however, continue beyond this phase, with the goal of submitting an application to the FDA within H1 2026. Additionally, ViroGates continues to progress towards an IVDR clearance of its products. These factors are reflected in the EBIT guidance for 2026.Jakob Knudsen, CEO of ViroGates, says: “We are making strong progress in transforming ViroGates into a player in the health management market. In this area, we are working in close collaboration with our distribution partners, setting shared goals for the markets we enter, mapping customer journeys, and identifying key bottlenecks that must be addressed to support customer acquisition and retention. We continue to serve hospital and research customers from our headquarters, rather than through local sales representatives as in the past, and the retention rates in this segment remain satisfactory.”For further information, please contact: ViroGates A/S: CEO, Jakob Knudsen Tel. (+45) 2226 1355, email: <a rel="noopener" href="mailto:jk@virogates.com">jk@virogates.com</a>Certified Advisor: Västra Hamnen Corporate Finance Per Lönn Tel. (+46) 40 200 250, email: <a rel="noopener" href="mailto:per.lonn@vhcorp.se">ca@vhcorp.se</a>About ViroGates ViroGates A/S is an international medical technology company that develops blood tests to measure inflammation in individuals at health clinics and improve patient care in hospitals. ViroGates markets its blood test products under the suPARnostic® brand.The company was founded in 2000. Headquartered in Denmark, ViroGates’ sales force covers Spain, France, and Benelux, while distributors serve other markets. ViroGates’ shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit <a rel="noopener" href="http://www.virogates.com/">www.virogates.com</a>.</div><div class="mfn-footer mfn-attachment mfn-attachment-general">Attachments <a rel="noopener" href="https://storage.mfn.se/34266764-862e-4013-a837-78fe01a0929e/20251212-virogates-comp-ann-22-financial-guidance.pdf" class="mfn-primary">20251212 ViroGates Comp Ann 22 Financial Guidance</a></div>